IE32140B1 - Vaccines - Google Patents

Vaccines

Info

Publication number
IE32140B1
IE32140B1 IE713/68A IE71368A IE32140B1 IE 32140 B1 IE32140 B1 IE 32140B1 IE 713/68 A IE713/68 A IE 713/68A IE 71368 A IE71368 A IE 71368A IE 32140 B1 IE32140 B1 IE 32140B1
Authority
IE
Ireland
Prior art keywords
informationally
viruses
antigen
vaccines
influenza
Prior art date
Application number
IE713/68A
Other languages
English (en)
Other versions
IE32140L (en
Original Assignee
Dieter Jachertz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dieter Jachertz filed Critical Dieter Jachertz
Publication of IE32140L publication Critical patent/IE32140L/xx
Publication of IE32140B1 publication Critical patent/IE32140B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IE713/68A 1967-06-19 1968-06-17 Vaccines IE32140B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEJ0033936 1967-06-19

Publications (2)

Publication Number Publication Date
IE32140L IE32140L (en) 1968-12-19
IE32140B1 true IE32140B1 (en) 1973-04-18

Family

ID=7204943

Family Applications (1)

Application Number Title Priority Date Filing Date
IE713/68A IE32140B1 (en) 1967-06-19 1968-06-17 Vaccines

Country Status (13)

Country Link
AT (1) AT282821B (en:Method)
BE (1) BE716806A (en:Method)
BR (1) BR6899970D0 (en:Method)
CH (1) CH513241A (en:Method)
DE (1) DE1617545C2 (en:Method)
DK (1) DK119724B (en:Method)
ES (1) ES355121A1 (en:Method)
FR (2) FR1588820A (en:Method)
GB (1) GB1229888A (en:Method)
IE (1) IE32140B1 (en:Method)
IL (1) IL30168A (en:Method)
NL (1) NL6808486A (en:Method)
NO (1) NO124840B (en:Method)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754934A (fr) * 1969-08-16 1971-02-17 Jachertz Diether Procede de production enzymatique d'arn-messager
GB1594097A (en) 1976-12-16 1981-07-30 Int Inst Of Differentiation Production of specific immune nucleic acids cell dialysates and antibodies
DE3115559A1 (de) * 1981-04-16 1982-10-28 Kommanditgesellschaft Schwarzhaupt, 5000 Köln Hochgereinigte informatorische ribonukleinsaeure (i-rns), verfahren zur herstellung und verwendung derselben
GB2216416B (en) * 1988-03-11 1992-06-24 Sandoz Ltd Nucleobase source for the stimulation of the immune system
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence

Also Published As

Publication number Publication date
BR6899970D0 (pt) 1973-02-13
AT282821B (de) 1970-07-10
BE716806A (en:Method) 1968-12-19
IL30168A0 (en) 1968-08-22
CH513241A (de) 1971-09-30
ES355121A1 (es) 1969-11-16
GB1229888A (en:Method) 1971-04-28
DE1617545C2 (de) 1983-11-03
IL30168A (en) 1973-05-31
FR1588820A (en:Method) 1970-03-16
IE32140L (en) 1968-12-19
DE1617545A1 (de) 1971-04-01
NL6808486A (en:Method) 1968-12-20
NO124840B (en:Method) 1972-06-12
DK119724B (da) 1971-02-15
FR7781M (en:Method) 1970-03-23

Similar Documents

Publication Publication Date Title
Milich Synthetic T and B cell recognition sites: implications for vaccine development
Wiktor et al. Cultivation of rabies virus in human diploid cell strain WI-38
Mumford et al. Studies with inactivated equine influenza vaccine: 2. Protection against experimental infection with influenza virus A/equine/Newmarket/79 (H3N8)
Oxford et al. The specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccines and by natural infection
Webster et al. Potentiation of the immune response to influenza virus subunit vaccines
US4117112A (en) Vaccine for prevention of feline leukemia
Atanasiu et al. Rabies neutralizing antibody response to different schedules of serum and vaccine inoculations in non-exposed persons: Part 3
IE32140B1 (en) Vaccines
JP2011525902A (ja) 遅延型追加刺激免疫処置に対する迅速な応答
US3927208A (en) Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them
Glasgow et al. Isoprinosine: lack of antiviral activity in experimental model infections
Reiss et al. Specificity of the helper T cell for the cytolytic T lymphocyte response to influenza viruses
Holper et al. Further studies on multiplication, serology and antigenicity of 2060 and JH viruses
Norrby et al. Humoral immunity to canine distemper after immunization of dogs with inactivated and live measles virus
Barbour et al. Comparison of Mycoplasma gallisepticum subunit and whole organism vaccines containing different adjuvants by western immunoblotting
Laver et al. Preparation and immunogenicity of a purified influenza virus haemagglutinin and neuraminidase subunit vaccine
US3629413A (en) Polyvalent bovine vaccines and methods of making and using same
US5006335A (en) Live vaccine against mumps and process for obtaining thereof
Millian et al. Antibody response of man to canine distemper virus
McLaren et al. Immunity to influenza in ferrets: XI. Cross-immunity between A/Hong Kong/68 and A/England/72 viruses: serum antibodies produced by infection or immunization
Srivastava et al. Studies on the immunogenicity of Streptococcus equi vaccines in foals
RU2092187C1 (ru) Инактивированная вакцина против сальмонеллеза овец
Norrby Characteristics of the progeny derived from multiplication of Sendai virus in a measles virus carrier cell line
RU2183972C2 (ru) Способ получения высокоактивной специфической к вирусу классической чумы свиней сыворотки крови свиней
JP5272129B2 (ja) インフルエンザウイルスの不活化抗原に対するアジュバント、及び分泌型IgA抗体誘導剤